samedan logo
 
 
spacer
home > ebr > summer 2002 > beyond borders - ernst & young's global biotechnology report 2002
PUBLICATIONS
European BioPharmaceutical Review

Beyond Borders - Ernst & Young's Global Biotechnology Report 2002

Reflecting the reality in which the global biotechnology industry now operates, Ernst & Young's Global Health Sciences Group recently launched the latest of their well-known regional biotechnology industry reports as a single global document at the recent annual international BIO Convention in Toronto in June. Beyond Borders - The Global Biotechnology Industry Report 2002, or 'global book' as those who have become familiar with this excellent publication describe it, is an extremely useful report for all interested participants in today's biotechnology marketplace. It is to be applauded for capturing not only the most up-to-date benchmark data on growth and financing trends but also the essence of the most pertinent issues for the global biopharma sector today.Assembled from knowledge researched within the different regional territories of Ernst & Young's Global Health Sciences Team, the report is divided into two sections. The first, The Global Marketplace, sets out data and trends from the global industry principally represented by the 25 countries that have fostered the growth of the sector and which are also responsible for 79 per cent of global gross domestic product.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Senior Consultant at Technomark Consulting Services
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement